SCHEMBL20424328

SCHEMBL20424328

CCCCCC/C(C=O)=C\c1ccc(F)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.72
LMNA P02545 2/20 0.69
TRPA1 O75762 5/20 0.48
GAA P10253 1/20 0.44
HTR7 P34969 1/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
PSMD14 O00487 1/20 0.39
HSP90AA1 P07900 1/20 0.39
MMP2 P08253 1/20 0.39
MC4R P32245 1/20 0.39
RAD52 P43351 1/20 0.39
ABCB11 O95342 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17444741 1.00 TDP1 (0.72) TDP1LMNATRPA1GAAHTR7
SCHEMBL20424330 1.00 TDP1 (0.72) TDP1LMNATRPA1GAAHTR7
SCHEMBL20424557 0.98 LMNA (0.71) TDP1LMNATRPA1GAAHTR7
SCHEMBL20424555 0.98 LMNA (0.71) TDP1LMNATRPA1GAAHTR7
SCHEMBL565591 0.86 TDP1 (0.74) TDP1LMNAGAANPSR1APP
SCHEMBL17444732 0.86 TDP1 (0.74) TDP1LMNAGAANPSR1APP
SCHEMBL565590 0.86 TDP1 (0.74) TDP1LMNAGAANPSR1APP
SCHEMBL20424869 0.85 TDP1 (0.54) TDP1LMNATRPA1GAAHTR7
SCHEMBL20424867 0.85 TDP1 (0.54) TDP1LMNATRPA1GAAHTR7
SCHEMBL17444740 0.84 TDP1 (0.72) TDP1LMNAMEN1CYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115710181-A Compounds for reducing perception of malodour and uses thereof 凯姆克姆公司 2023-02-24 CN disclosed
US-20220378675-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM S.A. (BE) 2022-12-01 US disclosed
CN-110494413-B Compounds for reducing perception of malodour and uses thereof 凯姆克姆公司 2022-11-22 CN disclosed
EP-4059917-A2 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF ChemCom S.A. (BE) 2022-09-21 EP disclosed
US-11382848-B2 Compounds reducing malodour perception and the use thereof CHEMCOM S.A. (BE) 2022-07-12 US disclosed
EP-3573944-B1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM SA (BE) 2022-03-02 EP disclosed
WO-2018138369-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM S.A. (BE) 2018-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11382848-B2 Compounds reducing malodour perception and the use thereof OR51E2, OR10J3, SRD5A1 TDP1 4689/4885LMNA 4749/4885TRPA1 72/4885
US-20220378675-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF OR51E2, OR10J3, SRD5A1 TDP1 4689/4885LMNA 4749/4885TRPA1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.